Accardi Mario Alberto 4

What Happened
Mario Alberto Accardi, CEO of Centessa Pharmaceuticals plc (CNTA), was awarded equity on Feb 2, 2026 and had a small share disposition for tax withholding. The filing shows: 68,000 restricted share units (RSUs) granted at $0, and 273,000 derivative awards (option-like) granted at $0. Separately, 2,915 shares were disposed on Feb 1 to cover tax withholding at $24.57 per share, totaling approximately $71,622. These were tax-withholding dispositions rather than open-market sales.

Key Details

• Transaction dates: Feb 1, 2026 (tax withholding disposition); Feb 2, 2026 (grants/awards). Filing date: Feb 3, 2026 (appears timely).
• Disposition: 2,915 shares withheld/disposed at $24.57 = $71,622 (footnote: shares withheld to cover tax withholding).
• Awards: 68,000 RSUs (issued under the 2021 Stock Option & Incentive Plan) and 273,000 derivative awards (both reported as acquired at $0).
• Vesting notes: RSUs vest in four equal annual installments, first vesting 2/2/2027; the derivative award vests 1/48th monthly, first installment vesting 3/2/2026.
• ADS note: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share, per footnote).
• Shares owned after the transactions are not disclosed in the provided filing excerpt.

Context
The 2,915-share disposition was a routine tax-withholding action tied to equity vesting and should not be read as a traditional sale signaling sentiment. The larger entries are grants—RSUs and a longer-term, monthly-vesting derivative award—so they increase potential future holdings only as they vest; they are not open-market purchases.